• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

CAR Cell In Vitro Cytotoxicity Assay Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The CAR Cell In Vitro Cytotoxicity Assay is a pivotal tool in assessing the efficacy and safety of CAR-T cell therapies. It plays a critical role in the preclinical evaluation of CAR-T constructs and the optimization of their functional characteristics. By simulating the In Vivo environment within an In Vitro setting, our service allows for a comprehensive evaluation of CAR-T cells, including their target-specific cytotoxicity, potency, and specificity.

Assay Overview

The cornerstone of the CAR Cell In Vitro Cytotoxicity assay lies in its ability to replicate the complex interplay between CAR-T cells and target cells, mimicking the tumor microenvironment. It involves co-culturing CAR-T cells with target cells expressing the relevant antigen. Creative Biolabs' expert team designs and customizes the assay to match the specific attributes of the CAR-T construct and the target antigen.

The assay measures cytotoxicity through various endpoints, including:

• Cytokine Release: The production of cytokines, such as IFN-γ and IL-2, reflects the activation and effectiveness of CAR-T cells.
• Target Cell Killing: The direct lysis of target cells by CAR-T cells provides a quantitative assessment of cytotoxicity.
• Proliferation: Monitoring the expansion of CAR-T cells over time can provide insights into their persistence and long-term efficacy.

Assay Workflow

Our service follows a structured workflow to ensure a comprehensive assessment of CAR-T cells:

Advantages of Our Service

• High Sensitivity and Specificity
  The CAR Cell In Vitro Cytotoxicity assay allows for the precise evaluation of CAR-T cell specificity and potency. It identifies even subtle differences in cytotoxicity, enabling the fine-tuning of CAR-T constructs.
• Cost-Effective Preclinical Screening
  Using this In Vitro assay can significantly reduce the cost and time associated with preclinical CAR-T cell therapy evaluation, making it an indispensable tool in the drug development process.
• Customization for Diverse CAR-T Constructs
  Creative Biolabs tailors the assay to accommodate different CAR-T constructs and target antigens, ensuring versatility and applicability across a wide range of research.
• Reduction of In Vivo Testing
  By providing a reliable and robust In Vitro alternative, our service minimizes the need for animal testing, aligning with ethical and regulatory standards.

For further information about our services, please reach out to us by email, and our dedicated team will promptly respond to your inquiries.